eXoZymes Inc. Common Stock EXOZ Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.44M-52.5% | $3.04M-40.4% | $5.1M-27.0% | $6.99M-17.9% | $8.51M-12.4% | ||
| $2.09M-46.9% | $3.94M-29.7% | $5.61M-25.6% | $7.53M-20.0% | $9.42M-13.0% | ||
| $747.86K-2.2% | $764.4K+0.2% | $763.01K-7.1% | $821.31K-2.6% | $842.99K-4.5% | ||
| —— | —— | —— | —— | —— | ||
| $4.02M-32.7% | $5.97M-22.6% | $7.72M-20.2% | $9.68M-16.0% | $11.53M-11.6% | ||
| $1.23M-0.1% | $1.24M+36.6% | $904.35K-2.8% | $930.63K-13.2% | $1.07M+16.0% | ||
| $45.1K+1.9% | $44.26K+3.8% | $42.62K0.0% | $42.62K— | —— | ||
| $1.58M+1.0% | $1.57M+26.5% | $1.24M+1.8% | $1.22M-15.7% | $1.44M+8.3% | ||
| $1.27M-56.4% | $2.92M-42.8% | $5.1M-27.0% | $6.99M-14.4% | $8.16M+212% | ||
| 100M0.0% | 100M0.0% | 100M0.0% | 100M0.0% | 100M0.0% | ||
| -$23.47M-11.2% | -$21.1M-14.4% | -$18.45M-14.1% | -$16.16M-17.1% | -$13.8M-15.5% | ||
| $1.53M-55.0% | $3.4M-36.8% | $5.37M-25.7% | $7.24M-18.5% | $8.88M-14.8% | ||
| $4.02M-32.7% | $5.97M-22.6% | $7.72M-20.2% | $9.68M-16.0% | $11.53M-11.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are eXoZymes Inc. Common Stock's total assets?
- eXoZymes Inc. Common Stock (EXOZ) holds $4.0M in total assets, down 65.1% year over year.
- How much debt does eXoZymes Inc. Common Stock have?
- eXoZymes Inc. Common Stock carries $1.2M in total debt against $1.5M of shareholders' equity, a debt-to-equity ratio of 0.79.
- How much cash does eXoZymes Inc. Common Stock have?
- eXoZymes Inc. Common Stock holds $1.4M in cash and equivalents.
- Can eXoZymes Inc. Common Stock cover its short-term obligations?
- Its current ratio is 1.32 — current assets exceed current liabilities.
- Where does eXoZymes Inc. Common Stock's balance sheet data come from?
- Every line is extracted from eXoZymes Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
